All Articles

As Indonesia Energy Corp drills its K-29 well, we explore the strategy behind the spin. Is this about barrels of oil or building investor confidence?

Abeona Therapeutics celebrates rising sales for its life-changing RDEB therapy, ZEVASKYN. But behind the numbers lies a story of manufacturing hurdles and mounting debt.

Revenue is down, but Bragg Gaming's margins are up. A new chairman, a major acquisition, and deep cuts signal a high-stakes bet on a leaner future.

NervGen Pharma launches its pivotal Phase 3 RESTORE trial for spinal cord injury, backed by $61M in cash and new leadership, igniting hope for a new era of neuro-repair.

MSG Sports posts record profits fueled by a Knicks NBA title, but the real story is the strategic gamble to split its empire, creating long-term risks.

NeuPath Health's Q2 results show headline declines, but a deeper look reveals strong organic growth from record patient visits and strategic expansion.

PO Wealth Sharing Group claims 200,000 users and a global footprint. But beneath the surface of this fintech success story lies a troubling pattern.

The FDA is betting on AI to manage chronic illness. Cadence's new pilot for its hypertension software could rewrite the rules for digital health regulation.

Facing a 'going concern' warning, Pulmatrix abandons its drug pipeline for a reverse merger, betting its survival on the high-risk field of longevity science.

A new partnership between Flip Electronics and Vishay confronts the growing crisis of component obsolescence, promising a secure, authorized channel for legacy parts.

ImpactFactory.ai launches a platform integrating 25+ AI engines to automate marketing, promising to democratize advertising. But what does this mean for the human creative?

Rigel's VEPPANU is the first FDA-approved PROTAC, a new class of drug that destroys disease proteins. This is the story behind the science and the numbers.

With a giant copper resource, Minsud Resources uses a clever partnership with South32 to fund a 10,500m drill program while preserving capital.

A Washington nonprofit reports a stunning 6% recidivism rate, far below national averages. We dissect the model combining aerospace manufacturing with social reform.

Beyond the polish, the rise of companies like Pudu Robotics reveals the real story: an AI-driven digital infrastructure is quietly rewiring our cities.

Curis secures a crucial, albeit small, $5.6M funding lifeline. Will it be enough to push its promising cancer drug through trials before the clock runs out?

Lucid Diagnostics reports rising revenue and a key insurance win for its EsoGuard test, but its financial future hangs in the balance of a pivotal Medicare decision.

A startup's revolutionary 'space sling' just won a massive Space Force contract. Here's why this fuel-free platform could redefine orbital warfare.

Biomea Fusion's new trial combines its drug icovamenib with semaglutide, aiming not just for weight loss, but to solve a major side effect: muscle loss.

Despite a sharp performance dip in July driven by an AI stock selloff, investors continue to pour capital into hedge funds for the seventh straight month.